Skip to main content

Grafa News and Videos — Page 1291

Latest

Grafa

Pfizer’s Hympavzi gains EU approval for hard-to-treat hemophilia patients

Pfizer (NYSE:PFE) announced Wednesday that European regulators have cleared Hympavzi for adolescents and adults with hemophilia A or B with inhibitors, marking a significant expansion for the non-factor therapy in the 27 EU member states, Iceland, Liechtenstein, and Norway.

Read more: Pfizer’s Hympavzi gains EU approval for hard-to-treat hemophilia patients

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift